Seabridge Gold Announces Closing of $15.7 Million Bought Deal Public Offering of Common Shares
Apr 19, 2017 12:45 pm UTC| Business
TORONTO, April 19, 2017 -- Seabridge Gold Inc. (TSX:SEA) (NYSE:SA) (the “Company” or “Seabridge”) announced today that it has closed its previously announced bought deal public offering (the “Public Offering”) of common...
KEMET Completes Acquisition of NEC TOKIN
Apr 19, 2017 12:31 pm UTC| Business
GREENVILLE, S.C., April 19, 2017 -- KEMET Corporation (the “Company” or “KEMET”) (NYSE:KEM), a leading global supplier of passive electronic components, announced today that it has completed the acquisition, through its...
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering
Apr 19, 2017 12:31 pm UTC| Business
EDEN PRAIRIE, Minn., April 19, 2017 -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today the pricing of an underwritten public offering of units for gross proceeds of $8.0 million, prior to deducting underwriting...
KEMET Completes Acquisition of NEC TOKIN
Apr 19, 2017 12:31 pm UTC| Business
GREENVILLE, S.C., April 19, 2017 -- KEMET Corporation (the “Company” or “KEMET”) (NYSE:KEM), a leading global supplier of passive electronic components, announced today that it has completed the acquisition, through its...
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering
Apr 19, 2017 12:31 pm UTC| Business
EDEN PRAIRIE, Minn., April 19, 2017 -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today the pricing of an underwritten public offering of units for gross proceeds of $8.0 million, prior to deducting underwriting...
Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting
Apr 19, 2017 12:31 pm UTC| Business
SAN DIEGO and TORONTO, April 19, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today...
Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting
Apr 19, 2017 12:31 pm UTC| Business
SAN DIEGO and TORONTO, April 19, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today...